“teva-pharmaceutical-industries” Archives

in
Entry Author Date Location
Weeks After Deal, FDA Slaps Clinical Hold on Regeneron/Teva Pain Drug 10/17/16 New York
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Regeneron, in Pain Drug Race With Pfizer & Lilly, Gets $250M From Teva 09/20/16 New York
In Race to Relief, Amgen Touts New But Incomplete Migraine Data 06/09/16 San Francisco
Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes 06/03/16 National
With New Data, Alder Keeps Pace in Migraine Drug Race 03/28/16 Seattle
WaVe, Voyager Get $170M Combined in Biotech’s Latest IPO Tests 11/11/15 Boston
In New York, Rgenix Rises From Rockefeller and Takes Aim at Cancer 08/31/15 New York
East Coast Biotech Roundup: Editas, Checkmate, Ovid & More 08/14/15 Boston
Ex-Teva CEO’s Brain Disease Startup, Ovid, Bags $75M From Crossovers 08/11/15 New York
East Coast Biotech Roundup: PrecisionFDA, Avitide, Foresight & More 08/07/15 Boston
East Coast Biotech Roundup: Emulate, Pulmatrix, Synergy & More 06/19/15 New York
West Coast Biotech Roundup: Auspex, Hyperion, NuVasive, & More 04/02/15 San Diego
Teva Agrees to Buy San Diego’s Auspex Pharmaceuticals for $3B+ 03/30/15 San Diego
West Coast Biotech Roundup: Juno, Nektar, Kite, Glooko & More 03/19/15 Seattle
VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma 07/02/14 San Diego
As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund 06/10/14 San Francisco
GenSpera’s Targeted “Death Carrot” Toxin in Trials for Two Cancers 03/27/14 Texas
Cocrystal Discovery Lands $7,500,000 New Funding Round 09/15/11 Seattle
Ironwood Pharmaceuticals Sells Struggling Microbia Subsidiary to Royal DSM 09/22/10 Boston
Genzyme Activist Joins Board, Agios Clinches Deal With Celgene, Third Rock Seeks $400M New Fund, & More Boston-Area Life Sciences News 04/16/10 Boston
Nokia Acquires Metacarta, Massachusetts Taps EnerNOC and FloDesign, MedVentive Gets Backing from Clarian Health, & More Boston-Area Deals News 04/14/10 Boston
Mersana Strikes Deal With Teva Worth up to $334M for Long-Lasting Cancer Drug 04/13/10 Boston
Page 1 of 1